Regeneron Reports the US FDA Acceptance of sBLA for Review of Libtayo (cemiplimab) to Treat Advanced Non-Small Cell Lung Cancer
Shots:
- The sBLA is based on the P-III trial evaluating Libtayo + Pt-doublet CT vs CT alone in 466 patients with LA or metastatic NSCLC regardless of PD-L1 expression level or tumor histology with no ALK, EGFR, or ROS1 aberrations. The FDA’s decision is expected on Sept 19, 2022.
- The results showed an improvement in OS, treatment discontinuations due to AEs (5% & 3%), patients with immune-mediated AEs & ECOG 1 (19% & 84%), 43% & 67% had tumors with sq. histology & <50% PD-L1 expression, 15% not eligible for chemoradiation & 7% had clinically stable brain metastases
- Libtayo is approved in the US & EU as a monothx. for patients with ≥50% PD-L1 expression
Ref: Regeneron | Image: Barron's
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com